Skip to Content
Søg Menu
Vi dækker

ESMO I European Society for Medical Oncology

ESMO 2024

Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
ESMO24Brystcancer Play the Video

Få adgang

Som læge, sygeplejerske eller anden sundhedsfaglig kan du få adgang til online artikler, MEDtalks, MEDcasts og meget mere, når du har tilmeldt dig og er blevet godkendt som bruger.

Få adgang

ESMO24: Immunotherapy Plus Chemotherapy Improves Progression-Free Survival in Metastatic Anal Cancer

/ Jan Andreasen
ESMO24Colorektalcancer
Hildur Helgadottir

The Effect of Adjuvant Treatment on Overall Survival in Melanoma Stage III Patients

/ Hildur Helgadottir
ESMO24Melanom Play the Video
Nancy Lin

New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

/ Nancy Lin
ESMO24Brystcancer Play the Video

ESMO24: First-Line Immunotherapy Combination Improves Overall Survival in HER2-Positive Metastatic G/GEJ Adenocarcinoma

/ Jan Andreasen
ESMO24Esofaguscancer
Petros Grivas

Avelumab Maintenance Is a Standard of Care Option for Patients with Advanced Urothelial Carcinoma

/ Petros Grivas
ESMO24Blærecancer Play the Video

ESMO24: New Standard of Care – Immunotherapy in High-Risk Locally Advanced Cervical Cancer

/ Jan Andreasen
ESMO24Gynækologisk cancer
Live Fagereng

Necessary to Evaluate and Justify Off-Label Use of Oncology Drugs to Provide Equal Access to Effective Treatment

/ Live Fagereng
ESMO24Cancer Play the Video

New Data on Trastuzumab Deruxtecan Shows Promising Outcomes in HER2-Positive Metastatic Breast Cancer with Brain Metastases: Results from DESTINY-Breast12

/ Jan Andreasen
ESMO24Brystcancer
Martin Højgaard

Durable Responses and Stable Disease in Multiple ATM-Altered Advanced Cancers

/ Martin Højgaard
ESMO24Cancer Play the Video
Katriina Jalkanen

Belzutifan is Well-Tolerated and Might Be an Addition to a Standard of Care

/ Katriina Jalkanen
ESMO24Nyrecancer Play the Video
Hanna Grauers Wiktorin

Objective Responses and Stable Disease in Patients with Immunotherapy Refractory Advanced Malignant Melanoma

/ Hanna Grauers Wiktorin
ESMO24Melanom Play the Video

ESMO24: Breastfeeding After Breast Cancer Treatment Is Safe

/ Sofie Pohl
ESMO24Brystcancer

BestPractice Nordic Covers ESMO 2024 – the Meeting of Forever Practice-Changing Trials

/ BestPractice Nordic
ESMO24
Mansoor Raza Mirza

ESMO: Update on the ENGOT-EN6 RUBY Trial

/ Mansoor Raza Mirza
ESMO24Gynækologisk cancer Play the Video
Hent flere

ESMO 2023

Endometriecancer: PD-L1 hæmmer i kombination med PARP-hæmmer reducerer signifikant progressionsfri overlevelse

/ Anja Ør Knudsen
ESMO23Brystcancer

KEYNOTE-522 viser forsat forbedret event-fri overlevelse for patienter med triple-negativ brystcancer

/ Ann Søegaard Knop
ESMO23Brystcancer
Peter Schmid

Pembrolizumab + Chemotherapy: a New Standard of Carefor Triple-Negative Breast Cancer

/ Peter Schmid
ESMO23Brystcancer Play the Video

Utvalgte ESMO 2023 Høydepunkter: Prostatakreft

/ Onkologi / Daniel Heinrich

ESMO 2023 Highlights: Practice-Changing Research in Gynecologic Cancers

/ Onkologi / Kristina Lindemann

Two New Potential Game-Changers in the Treatment of Gastroesophageal Cancer

/ Onkologi / Lene Bæksgaard

ESMO 2023: Dobling av overlevelsesraten ved innovativ behandling for metastatisk blærekreft

/ Onkologi / Daniel Heinrich

Potential New Standard of Care for Locally Advanced Cervical Cancer

/ Onkologi / Kristina Lindemann

ESMO 2023 • Meet the experts

Get access
Mansoor Raza Mirza

Optimizing PARP Inhibitor Therapy for Ovarian Cancer

/ Mansoor Raza Mirza
ESMO23Gynækologisk cancer Play the Video
Peter Meldgaard

Spændende data om adjuverende behandling til ALK-translokerede patienter og lavstadiet lungecancer

/ Peter Meldgaard
ESMO23Lungecancer Play the Video
Ellinor Haukland

Enabling Patient Empowerment Through Digital Monitoring

/ Ellinor Christin Haukland
ESMO23Patientinddragelse Play the Video
Marco Donia

ESMO 2023 Highlights: Developments in Melanoma

/ Marco Donia
ESMO23Melanom Play the Video
Jonathan Spicer

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

/ Jonathan Spicer
ESMO23Lungecancer Play the Video
Henrik Grönberg

Prostate Cancer: Adaptive, Biomarker-Driven Platform Trial Shows That New Hormonal Agents Have Better Efficacy for mCRPC

/ Henrik Grönberg
ESMO23Prostatacancer Play the Video

Selected ESMO 2023 Highlights: Endometrial Cancer Treatment

/ Shannon Westin
ESMO23Gynækologisk cancer Play the Video
Mansoor Raza Mirza

New Treatment Possibilities for Patients with Recurrent or Primary Advanced Endometrial Cancer

/ Mansoor Raza Mirza
ESMO23Gynækologisk cancer Play the Video
Karin Brochstedt Dieperink

Sygeplejerskens centrale rolle i behandlingen af senfølger

/ Karin Dieperink
ESMO23 Play the Video
Shannon Westin

Insights on DUO-E Trial: Advancing Endometrial Cancer Treatment with Olaparib

/ Shannon Westin
ESMO23Gynækologisk cancer Play the Video
Jaffer Ajani

Findings from the SPOTLIGHT Study Demonstrate the Power of the New Biomarker Claudin-18.2.

/ Jaffer Ajani
ESMO23Gastrointestinal cancer Play the Video
Arlene Siefker-Radtke

Urothelial Cancer: One Step Forward to Understand How to Combine and Sequence Treatments Against Novel Targets

/ Arlene O. Siefker-Radtke
ESMO23Blærecancer Play the Video
Hent flere

MEDtalks fra ESMO 2022

ESMO20: Update om lungecancer

/ Onkologi / Bjørn Henning Grønberg

ESMO20: Improved OS rate for metastatic, PD-L1-positive lung cancer patients

/ Onkologi / Julie Brahmer

ESMO20: First new drug in years reduces recurrence in high-risk hormone receptor positive early breast cancer

/ Onkologi / Stephen Johnston

ESMO20: KEYNOTE 590 will change practice for patients with oesophagus Cancer

/ Onkologi / Ken Kato

ESMO20: New first-line treatment option for metastatic kidney cancer

/ Onkologi / Toni K. Choueiri
Se oversigt

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

/ Onkologi / Nadia Harbeck

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Onkologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Onkologi / Jon Amund Kyte

The clinical value of circulating tumor DNA in bladder and renal cancer

/ Onkologi / Lars Dyrskjøt Andersen

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann

Tema: Lungecancer

Siow Ming Lee

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Siow Ming Lee
ESMO22NSCLCLungecancer Play the Video

New Tendencies in Development of ALK-TKIs for Treatment of ALK-Rearranged NSCLC

/ Onkologi / Edyta Maria Urbanska

ASCO24: Very Exciting Steps for Early Diagnosis and Lung Cancer

/ Onkologi / Oluf Dimitri Røe

Younger Patients with Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors Seem to be Prone to Return to Work

/ Onkologi / Edyta Maria Urbanska

Kan ctDNA bruges som klinisk værktøj hos patienter med avanceret ikke-småcellet lungekræft?

/ Onkologi / Michael Elmkvist Andersen

Carboplatin is a Viable Option in Treating Patients with Completely Resected Non-Small Cell Lung Cancer

/ Onkologi / Vivi Quoc Nguyen

Abstracts fra ESMO 2022

MCED blood test – a gamechanger for early cancer detection for cancer

/ BestPractice Nordic
ESMO22Cancer

Air pollution and lung cancer in never-smoking people 

/ BestPractice Nordic
ESMO22Lungecancer

Tumor-infiltrating lymphocytes improves PFS in metastatic melanoma

/ BestPractice Nordic
ESMO22Melanom
Hent flere

ESMO 2021

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Eric Pujade-Lauraine
ESMO21Gynækologisk cancer Play the Video
Silvia Stacchiotti

Global consensus: Management of epithelioid hemangioendothelioma

/ Silvia Stacchiotti
ESMO21Cancer Play the Video
Eric Pujade-Lauraine

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Eric Pujade-Lauraine
ESMO21Gynækologisk cancer Play the Video
Alan Celik

HER2-positiv brystcancer – fremtidige behandlingsmuligheder

/ Alan Celik
HER2ESMO21Brystcancer Play the Video
Lene Bæksgaard Jensen

Opdatering på CheckMate 649-studiet

/ Lene Bæksgaard
ESMO21Kemoterapi Play the Video
Dana Chase

High-risk factors in patients with advanced ovarian cancer impact survival

/ Dana Chase
ESMO21Gynækologisk cancer Play the Video
Hent flere

MEDtalks fra ESMO 2020

Højdosis strålebehandling ved småcellet lungekræft i begrænset stadium

/ Bjørn Henning Grønberg
LungecancerESMO20

PIONeeR-studiet bringer os tættere på forståelsen af resistens mod PD-1/L1 inhibitorer

LungecancerESMO20

Lovende effekt på hjernemetastaser placerer osimertinib som adjuverende behandling af EGFR-positiv ikke-småcellet lungecancer

HjernemetastaserLungecancerESMO20

Lorlatinib har potentiale til at blive ny førstelinjebehandling til lokal fremskreden og metastatisk ALK positiv NSCLC

NSCLCLungecancerESMO20

ESMO20: Kombinationsbehandling i første linje ved nyrecancer

/ Daniel Heinrich
ESMO20Nyrecancer Play the Video

Sacituzumab Govitecan er en ny lovende behandling til 2/3 linje triple-negativ avanceret brystkræft

BrystcancerESMO20
Se mere fra ESMO
Back to top